Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging

• DOI: 10.1007/s11307-022-01724-2
• Publication Date: 2022-04-11T19:08:21Z
• Authors: Kathia De Man; Sarah Piron; Nick Van Laeken; Louke Delrue; Valérie Fonteyne; Nicolaas Lumen; Bliede Van den Br...; Ken Kersemans; Piet Ost; Vanessa Schelfhout
• Keywords: PET-CT; Biochemical recurrence

In this study, we evaluated the impact of 18F-PSMA-11 PET/CT on the patient management plan in patients with primary or recurrent disease. Furthermore, a correlation between PET findings and other modalities was performed.In this prospective observational study, 60 prostate cancer patients (9 primary staging, 51 biochemical recurrence) were imaged with 18F-PSMA-11 PET/CT. Pre- and post-scan questionnaires were completed by the treating physician to observe changes in therapy intent. Follow-up data (histological confirmation, MRI imaging, and PSA values after radiotherapy without implementation of systemic therapy) was correlated with the 18F-PSMA-11 findings.The patient-based detection rate was 82% and a management change was seen in 52% of the cases. The heterogeneous characteristics of the included patients resulted in a widely varying treatment change, mostly originating from an increase of disease extent on 18F-PSMA-11 PET/CT.18F-PSMA-11 PET/CT showed to be a highly promising method for the detection of prostate cancer lesions.